Keeping Track: TGT’s Ukoniq Is Latest PI3K Inhibitor To Fall; GSK’s Daprodustat, Aeglea’s Pegzilarginase Headline Submissions

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

Keeping Track Feature image

The heat on the phosphatidylinositol 3-kinase (PI3K) inhibitor class is ratcheting up, with TG Therapeutics, Inc.’s Ukoniq joining the ranks of withdrawn products and an FDA advisory committee addressing the class-wide safety concerns.

The withdrawal of Ukoniq from the market as well as the pulling of applications for Ukoniq and an anti-CD20 antibody,...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers